Pentadeca Arginate (PDA)
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Pentadeca Arginate is marketed as an arginate-salt form of the BPC-157 pentadecapeptide for tissue repair and inflammation. It is not FDA-approved, and direct published human trials of PDA itself are essentially absent. Claims are mostly extrapolated from BPC-157 animal literature and should be considered research-use only.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Pentadeca Arginate (PDA) is a peptide most often used for bpc-157-related tissue repair claims, animal wound-healing literature for related peptide, no direct high-quality human pda evidence. NutriStack rates the overall evidence as insufficient. A typical adult dose is No FDA-approved human dose; no evidence-based PDA dose exists, commonly taken as not recommended for human use; research reagent only. This profile indexes 3 sources.
The bottom line
Evidence rating insufficient. Most-documented uses: bpc-157-related tissue repair claims, animal wound-healing literature for related peptide, no direct high-quality human pda evidence. 3 sources indexed (1997–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
PDA is described commercially as the BPC-157 peptide sequence paired with an arginine counterion, proposed to improve stability or formulation characteristics. BPC-157 literature suggests effects on nitric oxide pathways, angiogenesis, tendon and gut injury models, and cytoprotection, but most data come from animal models. The arginate salt should not be assumed to have proven human bioavailability, safety, or efficacy.1,3
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Laboratory Research Reagent.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Unknown long-term safety
- Injection-site reaction
- Nausea
- Headache
- Possible blood pressure changes through nitric oxide pathways
- Product contamination or mislabeling risk
Contraindications
- Any unsupervised human use
- Pregnancy and breastfeeding
- Active cancer or unexplained mass
- Severe vascular disease or uncontrolled blood pressure without clinician supervision
- Tendon rupture, GI bleeding, or serious injury needing medical care
- Use of research-grade injectable products
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Reviews & position papers
2- 1Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent ReviewDuzel A et al. · Pharmaceuticals · 2025
Many proposed applications are preclinical
- 2Stable Gastric Pentadecapeptide BPC 157 and Wound HealingSeiwerth S et al. · Frontiers in Pharmacology · 2021
Broad wound model literature reviewed
Mechanistic & preclinical
1- 3The influence of a novel pentadecapeptide, BPC 157, on NG-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressureSikiric P et al. · European Journal of Pharmacology · 1997
BPC-157 modified L-NAME and L-arginine effects
Common questions.
Quick answers about Pentadeca Arginate (PDA), drawn from the data on this page.
What is Pentadeca Arginate (PDA)?
Pentadeca Arginate is marketed as an arginate-salt form of the BPC-157 pentadecapeptide for tissue repair and inflammation. It is not FDA-approved, and direct published human trials of PDA itself are essentially absent. Claims are mostly extrapolated from BPC-157 animal literature and should be considered research-use only.
What is Pentadeca Arginate (PDA) used for?
Commonly cited benefits of Pentadeca Arginate (PDA) include: BPC-157-related tissue repair claims; Animal wound-healing literature for related peptide; No direct high-quality human PDA evidence; Not FDA-approved. NutriStack rates the overall evidence as insufficient.
What is a typical dose of Pentadeca Arginate (PDA)?
A typical adult dose of Pentadeca Arginate (PDA) is No FDA-approved human dose; no evidence-based PDA dose exists. The commonly recommended form is Not recommended for human use; research reagent only. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Pentadeca Arginate (PDA)?
Reported side effects include unknown long-term safety, injection-site reaction, nausea, headache, possible blood pressure changes through nitric oxide pathways, product contamination or mislabeling risk. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Pentadeca Arginate (PDA)?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Pentadeca Arginate (PDA) in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.